PROTOCOL OF THE HYPERTENSION THERAPY WITH IRBESARTAN VERSUS EPLERENONE FOR OBESE HYPERTENSIVE PATIENTS (HEBRO)

Autor:	Charalampos Grassos, V. Kotsis, Rigas Kalaitzidis, P. Iliakis, Athanassios D. Protogerou, Dimitrios Tousoulis, Helen Triantafyllidi, Ioannis Papadakis, Th. Makris, Costas Thomopoulos, Dimitris P. Papadopoulos, Emmanuel A. Andreadis, Stella Douma, Apostolos I. Hatzitolios, Pantelis Zebekakis, Dimitris Konstantinidis, G.S. Stergiou, Demetrios Vlahakos, Maria E. Marketou, Kyriakos Dimitriadis, Constantinos Tsioufis, Michalis Doumas, Efstathios Manios
Rok vydání:	2019
Předmět:	medicine.medical_specialty Aldosterone Physiology business.industry medicine.disease Obesity Eplerenone law.invention chemistry.chemical_compound Irbesartan chemistry Randomized controlled trial law Internal medicine Internal Medicine medicine Cardiology Cardiology and Cardiovascular Medicine business medicine.drug
Zdroj:	Journal of Hypertension. 37:e220
ISSN:	0263-6352
DOI:	10.1097/01.hjh.0000572836.65860.be
Popis:	Objective:Hypertension and obesity often coexist and activation of the renin-angiotensin- aldosterone (RAS) axis plays a major pathophysiological role. Since obese hypertensive patients are less frequently controlled within-goal compared with hypertensives without obesity, we aimed to determine whet
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c92904191e75b70c041b495af207db93 https://doi.org/10.1097/01.hjh.0000572836.65860.be Zobrazit plný text záznamu